Which has higher valuation & earnings, PDSB or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is PDSB or CTOR more profitable?

Citius Oncology's return on equity of -99.47% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Citius Oncology N/A -99.47% -42.16%

Does the media refer more to PDSB or CTOR?

In the previous week, PDS Biotechnology had 8 more articles in the media than Citius Oncology. MarketBeat recorded 11 mentions for PDS Biotechnology and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat PDS Biotechnology's score of -0.07 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALPS or PDSB?

PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 3,759.35%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings & valuation, ALPS or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALPS Group Inc Ordinary Share N/A N/A -$980K $0.33 0.99 PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is ALPS or PDSB more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets ALPS Group Inc Ordinary Share N/A N/A N/A PDS Biotechnology N/A -346.02% -102.36%

Is PLRX or PDSB more profitable?

Pliant Therapeutics' return on equity of -49.64% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -49.64% -38.53% PDS Biotechnology N/A -346.02% -102.36%

Does the media prefer PLRX or PDSB?

In the previous week, PDS Biotechnology had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 11 mentions for PDS Biotechnology and 5 mentions for Pliant Therapeutics. PDS Biotechnology's average media sentiment score of -0.07 beat Pliant Therapeutics' score of -0.09 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ANVS or PDSB?

Annovis Bio is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is ANVS or PDSB more profitable?

Annovis Bio's return on equity of -318.08% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% PDS Biotechnology N/A -346.02% -102.36%

Does the media favor ANVS or PDSB?

In the previous week, PDS Biotechnology had 9 more articles in the media than Annovis Bio. MarketBeat recorded 11 mentions for PDS Biotechnology and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 beat PDS Biotechnology's score of -0.07 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts recommend PDSB or BOLD?

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 3,759.35%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PDSB or BOLD?

Boundless Bio is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A Boundless Bio N/A N/A -$58.20M -$2.86 N/A

Is PDSB or BOLD more profitable?

Boundless Bio's return on equity of -65.05% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Boundless Bio N/A -65.05% -41.14%

PDS Biotechnology (PDSB) Competitors

$0.23 -0.01 (-3.64%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$0.23 0.00 (-0.51%)

As of 08:52 AM Eastern

Compare

PDSB vs. CTOR, ALPS, PLRX, ANVS, and BOLD

Should you buy PDS Biotechnology stock or one of its competitors? PDS Biotechnology's main competitors and comparable companies include Citius Oncology (CTOR), ALPS Group Inc Ordinary Share (ALPS), Pliant Therapeutics (PLRX), Annovis Bio (ANVS), and Boundless Bio (BOLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PDS Biotechnology compare to Citius Oncology?

PDS Biotechnology (NASDAQ:PDSB) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

PDS Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market.

PDS Biotechnology presently has a consensus price target of $9.00, suggesting a potential upside of 3,759.35%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 625.69%. Given PDS Biotechnology's higher possible upside, equities analysts plainly believe PDS Biotechnology is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Citius Oncology's return on equity of -99.47% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Citius Oncology	N/A	-99.47%	-42.16%

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Citius Oncology is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

In the previous week, PDS Biotechnology had 8 more articles in the media than Citius Oncology. MarketBeat recorded 11 mentions for PDS Biotechnology and 3 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat PDS Biotechnology's score of -0.07 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Citius Oncology beats PDS Biotechnology on 8 of the 11 factors compared between the two stocks.

How does PDS Biotechnology compare to ALPS Group Inc Ordinary Share?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, PDS Biotechnology had 9 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 11 mentions for PDS Biotechnology and 2 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.45 beat PDS Biotechnology's score of -0.07 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company	Overall Sentiment
ALPS Group Inc Ordinary Share	Positive
PDS Biotechnology	Neutral

PDS Biotechnology is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALPS Group Inc Ordinary Share	N/A	N/A	-$980K	$0.33	0.99
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 3,759.35%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALPS Group Inc Ordinary Share	N/A	N/A	N/A
PDS Biotechnology	N/A	-346.02%	-102.36%

ALPS Group Inc Ordinary Share has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

ALPS Group Inc Ordinary Share beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Pliant Therapeutics' return on equity of -49.64% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-49.64%	-38.53%
PDS Biotechnology	N/A	-346.02%	-102.36%

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 177.78%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 3,759.35%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pliant Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

In the previous week, PDS Biotechnology had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 11 mentions for PDS Biotechnology and 5 mentions for Pliant Therapeutics. PDS Biotechnology's average media sentiment score of -0.07 beat Pliant Therapeutics' score of -0.09 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PDS Biotechnology has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	42.33	-$149.34M	-$1.84	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

PDS Biotechnology beats Pliant Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, PDS Biotechnology had 9 more articles in the media than Annovis Bio. MarketBeat recorded 11 mentions for PDS Biotechnology and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 beat PDS Biotechnology's score of -0.07 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Annovis Bio is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Annovis Bio presently has a consensus target price of $11.67, indicating a potential upside of 553.59%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 3,759.35%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Annovis Bio has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

Annovis Bio's return on equity of -318.08% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
PDS Biotechnology	N/A	-346.02%	-102.36%

Summary

PDS Biotechnology beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Boundless Bio?

PDS Biotechnology (NASDAQ:PDSB) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

PDS Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Boundless Bio's return on equity of -65.05% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Boundless Bio	N/A	-65.05%	-41.14%

26.8% of PDS Biotechnology shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Comparatively, 23.1% of Boundless Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, PDS Biotechnology had 10 more articles in the media than Boundless Bio. MarketBeat recorded 11 mentions for PDS Biotechnology and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat PDS Biotechnology's score of -0.07 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
PDS Biotechnology	Neutral
Boundless Bio	Positive

Boundless Bio is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 3,759.35%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PDS Biotechnology beats Boundless Bio on 9 of the 13 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.53M	$3.75B	$7.07B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-0.35	10.24	269.63	25.21
Price / Sales	N/A	1,291.38	596.72	99.91
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.30	17.68	13.11	6.24
Net Income	-$34.50M	-$13.30M	$3.45B	$347.70M
7 Day Performance	-69.92%	0.65%	0.78%	0.87%
1 Month Performance	-68.99%	0.50%	1.45%	0.90%
1 Year Performance	-80.57%	54.56%	67.07%	20.13%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	1.7129 of 5 stars	$0.23 -3.6%	$9.00 +3,759.3%	-79.9%	$13.53M	N/A	N/A	20	News Coverage Earnings Report High Trading Volume
CTOR Citius Oncology	2.0012 of 5 stars	$0.73 -1.0%	$6.00 +721.9%	-53.8%	$67.78M	N/A	N/A	N/A	Upcoming Earnings
ALPS ALPS Group Inc Ordinary Share	1.6904 of 5 stars	$0.39 -5.8%	N/A	N/A	$65.40M	N/A	1.19	N/A	Positive News Short Interest Decrease Gap Down
PLRX Pliant Therapeutics	2.2367 of 5 stars	$1.06 +1.4%	$3.00 +184.4%	-32.5%	$65.33M	$1.58M	N/A	90	Earnings Report
ANVS Annovis Bio	3.1943 of 5 stars	$1.89 -0.3%	$11.67 +518.9%	-33.9%	$65.32M	N/A	N/A	3	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. CTOR, ALPS, PLRX, ANVS, and BOLD

How does PDS Biotechnology compare to Citius Oncology?

Summary

How does PDS Biotechnology compare to ALPS Group Inc Ordinary Share?

Summary

How does PDS Biotechnology compare to Pliant Therapeutics?

Summary

How does PDS Biotechnology compare to Annovis Bio?

Summary

How does PDS Biotechnology compare to Boundless Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. CTOR, ALPS, PLRX, ANVS, and BOLD

How does PDS Biotechnology compare to Citius Oncology?

Which has more risk and volatility, PDSB or CTOR?

Do analysts rate PDSB or CTOR?

Is PDSB or CTOR more profitable?

Do institutionals and insiders have more ownership in PDSB or CTOR?

Which has higher valuation & earnings, PDSB or CTOR?

Does the media refer more to PDSB or CTOR?

Summary

How does PDS Biotechnology compare to ALPS Group Inc Ordinary Share?

Does the media favor ALPS or PDSB?

Which has higher earnings & valuation, ALPS or PDSB?

Do analysts prefer ALPS or PDSB?

Do institutionals & insiders believe in ALPS or PDSB?

Is ALPS or PDSB more profitable?

Which has more volatility & risk, ALPS or PDSB?

Summary

How does PDS Biotechnology compare to Pliant Therapeutics?

Is PLRX or PDSB more profitable?

Do analysts prefer PLRX or PDSB?

Which has more volatility and risk, PLRX or PDSB?

Does the media prefer PLRX or PDSB?

Do institutionals and insiders believe in PLRX or PDSB?

Which has better earnings & valuation, PLRX or PDSB?

Summary

How does PDS Biotechnology compare to Annovis Bio?

Does the media favor ANVS or PDSB?

Which has preferable valuation and earnings, ANVS or PDSB?

Do analysts rate ANVS or PDSB?

Do insiders and institutionals believe in ANVS or PDSB?

Which has more risk and volatility, ANVS or PDSB?

Is ANVS or PDSB more profitable?

Summary

How does PDS Biotechnology compare to Boundless Bio?

Which has more volatility and risk, PDSB or BOLD?

Is PDSB or BOLD more profitable?

Do institutionals & insiders have more ownership in PDSB or BOLD?

Does the media prefer PDSB or BOLD?

Which has higher valuation & earnings, PDSB or BOLD?

Do analysts recommend PDSB or BOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools